

ASX Release

SUDA LTD AUDIO WEBCAST

PERTH, AUSTRALIA – 1 December 2016: SUDA LTD (ASX: SUD), a leader in oro-mucosal drug delivery, provides the opportunity to listen to an audio broadcast with Mr Stephen Carter, SUDA's Managing Director & CEO, in a presentation titled:

SUDA Ltd and Eddingpharm Enter Licensing Agreement for ZolpiMist in China.

Access this webcast at:

<https://boardroom.media/broadcast/?refid=&eid=583e55fb12b3a5e338c0ec3a>



Further information:

STEPHEN CARTER

CHIEF EXECUTIVE OFFICER / MANAGING DIRECTOR

SUDA LTD

Tel: +61 8 6142 5555

sjcarter@sudaltd.com.au

NOTES TO EDITORS:

About SUDA LTD

SUDA LTD (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using its OroMist® technology to reformulate existing pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (ie: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes Zolpimist™, a first-in-class oral spray of zolpidem for insomnia. Zolpimist™ is marketed in the USA and SUDA has rights to the product outside of North America. SUDA's most advanced development-stage product, ArTiMist®, is a novel sublingual malaria treatment for children. In a Phase III trial, ArTiMist® was shown to be superior to intravenous quinine. Other products in development include oral sprays for the treatment of migraine headache, chemotherapy-induced nausea and vomiting, erectile dysfunction and pre-procedural anxiety. For more information, visit www.sudaltd.com.au